Do Patterns of Instability or Severity of Psychopathology During Screening Predict Relapse in Schizophrenic Outpatient Subjects with Moderate to Severe Negative Symptoms Assigned to Placebo?
Background: Patients with schizophrenia who, prior to inclusion in placebo-controlled trials, experience the most severe and/or unstable symptoms might be more likely to manifest symptomatic worsening upon antipsychotic discontinuation. Methods: This retrospective analysis included all randomized pa...
| Publicado en: | Innovations in Clinical Neuroscience Vol. 17; no. 1/3; pp. 27 - 30 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | pictorial research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Matrix Medical Communications, LLC
Jan-Mar2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142927315&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 142927315 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 21588333 DAD5 jtl: Innovations in Clinical Neuroscience issn: 21588333 maglogo: N pubinfo: dt: Jan-Mar2020 vid: 17 iid: 1/3 pid: 33670 pub: Matrix Medical Communications, LLC place: West Chester, Pennsylvania artinfo: ui: 142927315 142927315 142927315 142927315 ppf: 27 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Do Patterns of Instability or Severity of Psychopathology During Screening Predict Relapse in Schizophrenic Outpatient Subjects with Moderate to Severe Negative Symptoms Assigned to Placebo? aug: au: DANIEL, DAVID G. KOTT, ALAN SAOUD, JAY LUTHRINGER, REMY RUD, VADYM SKYRPNIKOV, ANDRII STAN, RODICA PALAZOV, VESELIN XINGMEI WANG DAVIDSON, MICHAEL affil: Signant Health in Mclean, Virginia sug: subj: Schizophrenia Psychosocial Factors Psychopathology Severity of Illness Health Screening Recurrence Outpatients Placebos Human Randomized Controlled Trials Retrospective Design Double-Blind Studies Antipsychotic Agents Therapeutic Use Scales ab: Background: Patients with schizophrenia who, prior to inclusion in placebo-controlled trials, experience the most severe and/or unstable symptoms might be more likely to manifest symptomatic worsening upon antipsychotic discontinuation. Methods: This retrospective analysis included all randomized patients assigned to placebo (n=83) in a 12-week, double-blind, placebo-controlled outpatient trial of MIN-101 (roluperidone) for the treatment of negative symptoms in schizophrenia. The following risk factors were defined for exacerbation: instability between screening and baseline defined operationally as patients with the highest 10 percent of absolute change from the screening visit to baseline in the Positive and Negative Syndrome Scale (PANSS) total or one of the five PANSS Marder factors; screening or baseline severity in PANSS total or one of the five PANSS Marder factors; and gender and age. We used two operational criteria of relapse and the odds ratios of meeting the relapse criteria were calculated for each risk factor. Results: The odds of meeting one of the operational thresholds for relapse after antipsychotic discontinuation were not statistically significantly increased in the subjects who were unstable on the PANSS total or on one of the five PANSS Marder factors before antipsychotic discontinuation. Further, the severity of PANSS total and Marder factor scores at screening and baseline were not statistically significantly associated with odds of relapse. Neither age nor gender had any effect on relapse rates. Conclusion: Mild to moderate symptomatic variations in the severity of symptoms during screening and more severe symptomology at baseline as measured by the PANSS were not predictive of increased risk of subsequent relapse in schizophrenic patients. pubtype: Academic Journal doctype: pictorial research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|